SRS16-86 是 ferroptosis 的有效抑制剂。SRS16-86 在体内比 Ferrostatin-1 对代谢和血浆更稳定。SRS16-86 可用于肾缺血再灌注损伤 (IRI) 和脊髓损伤 (SCI) 研究。

SRS16-86 is a potent inhibitor of ferroptosis. SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research.

Solid

SRS16-86 (1 μM; 24 hours; in the presence or absence of erastin) inhibits ferroptosis in HT-1080 cells and NIH 3T3 cells.
has not independently confirmed the accuracy of these methods. They are for reference only.

SRS16-86 (intraperitoneal injection; 2 mg/kg; 15 min before the onset of surgery) protects mice from functional acute renal failure and structural organ damage after ischemia–reperfusion injury (IRI).
SRS16-86 (intraperitoneal injection; 2 mg/kg; 4 weeks) combination therapy with [Nec-1+SfA] is superior in the prevention of renal IRI compared with the double-combination therapy with [Nec-1+SfA]. Addition of 16-86 reduces plasma levels of serum urea and serum creatinine in IRI mice model.
SRS16-86 (intraperitoneal injection; 15 mg/kg; once a day; 7 days) enhances functional recovery after SCI, it decreases the levels of proinflammatory cytokines and the inflammatory adhesion factor in injured spinal cord in rats.
has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

[1]. Sam Hofmans, et al. Novel Ferroptosis Inhibitors with Improved Potency and ADME Properties. J Med Chem. 2016 Mar 10;59(5):2041-53.
[2]. Andreas Linkermann, et al. Synchronized renal tubular cell death involves ferroptosis.Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16836-41.
[3]. Yan Zhang, et al. Ferroptosis

In Vitro: DMSO : 33.33 mg/mL (77.05 mM; ultrasonic and warming and heat to 60°C)配制储备液